1 – 37 of 37
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cohort profile : the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)—acute coronary syndrome and percutaneous coronary intervention
(
- Contribution to journal › Article
- 2023
-
Mark
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
(
- Contribution to journal › Article
- 2022
-
Mark
Data standards for acute coronary syndrome and percutaneous coronary intervention : the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
(
- Contribution to journal › Article
-
Mark
European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes
(
- Contribution to journal › Scientific review
-
Mark
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
(
- Contribution to journal › Article
- 2021
-
Mark
The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)
(
- Contribution to journal › Article
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
- 2020
-
Mark
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
(
- Contribution to journal › Article
- 2019
-
Mark
A catalog of genetic loci associated with kidney function from analyses of a million individuals
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction
(
- Contribution to journal › Article
- 2018
-
Mark
Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention
(
- Contribution to journal › Article
-
Mark
Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years : experiences from SWEDEHEART registry 1995 to 2014
(
- Contribution to journal › Article
- 2017
-
Mark
Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments : experiences from the SWEDEHEART registry 1995-2014
(
- Contribution to journal › Article
-
Mark
Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk
(
- Contribution to journal › Article
-
Mark
A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors
(
- Contribution to journal › Article
-
Mark
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease : A molecular and genetic association study
(
- Contribution to journal › Article
- 2016
-
Mark
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction : Experiences from SWEDEHEART registry
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction - A registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)
(
- Contribution to journal › Article
-
Mark
Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
(
- Contribution to journal › Article
- 2015
-
Mark
Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.
(
- Contribution to journal › Article
-
Mark
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease : An analysis from the platelet inhibition and patient outcomes (plato) trial
(
- Contribution to journal › Article
-
Mark
Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction-Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials.
(
- Contribution to journal › Article
- 2014
-
Mark
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
(
- Contribution to journal › Article
-
Mark
Rapid Endovascular Catheter Core Cooling combined with cold saline as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction (The CHILL-MI trial).
(
- Contribution to journal › Article
- 2013
-
Mark
Large-scale association analysis identifies new risk loci for coronary artery disease
(
- Contribution to journal › Article
-
Mark
Discovery and refinement of loci associated with lipid levels
(
- Contribution to journal › Article
-
Mark
Common variants associated with plasma triglycerides and risk for coronary artery disease
(
- Contribution to journal › Article
- 2011
-
Mark
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-A case-control study
(
- Contribution to journal › Article
- 2010
-
Mark
1/4 av all vård är onödig eller skadlig
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment.
(
- Contribution to journal › Article
-
Mark
Niemann-Pick C1 Modulates Hepatic Triglyceride Metabolism and Its Genetic Variation Contributes to Serum Triglyceride Levels
(
- Contribution to journal › Article
-
Mark
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
(
- Contribution to journal › Article
- 2009
-
Mark
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
(
- Contribution to journal › Article
-
Mark
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
-
Mark
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
(
- Contribution to journal › Article
-
Mark
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
(
- Contribution to journal › Article